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ABSTRACT 
Objective: The sygnificance of this study is to find a new hexagamavunon-6 analogue (HGV-6); 3,5-bis-(4´-chlorobenzylidene)-tetrahydro-4H-
thiopyran-4-one (D144); 3,5-bis-(2´,4´-dichlorobenzylidene)-tetrahydro-4H-thiopyran-4-one (D154); 3,5-bis-(3´,5´-dichlor ro-4´-
hydroxybenzylidene)-tetrahydro-4H-thiopyran-4-one (D156) as a potential PBP-1A inhibitor. 
Methods: Docking method through Molecular Operating Environment (MOE) software was used to design a new HGV-6 analogue and study its 
interaction with penicillin binding protein (PBP-1a). This docking study used parameterized model 3 (PM3) method through Polak Ribiere algorithm to 
calculate the optimal structural geometry of the compound. Protein validation was carried out to ensure that the protein was suitable for use. 
Results: The results of the docking study show that the docking scores of D144 (-9.7942) and D154 (-10.1961) are higher than D156 (-12.2604), 
while D156 is lower than HGV-6 (-11.7958). Ampicillin (-13.6496) as a native ligand has the smallest docking score compared to the test 
compounds. 
Conclusion: The results of the docking study show that 3,5-bis-(3,5-dichloro-4-hydroxybenzylidene)-tetrahydro-4H-thiopyran-4-one (D156) has a 
better potential antibacterial compound than HGV-6. 
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INTRODUCTION 
The development of research on the new antibacterial drug for 
treating life-threatening infectious diseases is urgent. The 
development of antimicrobial resistance has increased during this 
century, so the development of new antimicrobial agents that are 
more selective, stronger and lower toxic than the drugs that have been 
used clinically is urgently needed. Curcumin, (E,E)-l,7-bis-(4-hydroxy-
3-methoxyphenyl)-l,6-heptadiene-3,5-dione, also known as turmeric, 
is a natural yellow pigment derived from the root of C. tinctoria, C. 
xanthorrhiza and C. domestica has been used for centuries. It is used as 
a food coloring agent and for traditional medication in India [1] to 
treat various diseases including billary disorder, anorexia, cough, 
diabetic wounds [2], many types of cancer, antiinflammatory [3], 
antispasmodics, antimicrobial [4], antimicrobiota for digestive tract.  
Monocarbonyl analogue of curcumin (MAC) no 74-94 by 
curcumin 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiena-
3,5-dion has gained a lot of attention from researchers [5]. The 
effect of curcumin structural modification can increase stability 
and solubility, which involve the elimination of keto-enol forms 
which are prone to hydrolysis, including various alternative 
substituents on the terminal phenyl ring [6]. In the design of 
modern drug, molecular docking is regularly used to find out 
drug receptor interactions. Molecular docking provides useful 
information about the drug receptor interactions and is often 
used to predict the orientation of the candidate bonds of small 
molecule drugs with target protein to predict molecular affinity 
and activity [7]. 
Istyastono [8] had carried out molecular analogue of curcumin to 
obtain lead compounds in the development of dipeptidyl peptidase-
4 inhibitor. Yuniarti [9] had also conducted in vitro and in silico 
studies on curcumin and its analogues as dual inhibitors of 
cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) fig. 1. 
 
 
Fig. 1: Modification of HGV-6 
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New analogues of HGV-6 compounds with the codes D144, D154 and 
D156 with the main chain S-heterocyclic, substituents of chlorine (-
Cl), hydroxy (-OH) in the side chain and imidazole analogue [10] 
suspected to have activities such as HGV-6. Screening of the three 
compounds is used as a basis for the presence or absence of changes 
in the substitutes for their antibacterial activity. 
Penicillin binding proteins (PBPs) are enzymes for the 
polymerization of the glycan strands and the cross-linking between 
glycan chain and the target protein for β-lactam antibiotics. 
Mutational changes in PBP can cause resistance either by reducing 
the antibiotic binding to the active site or by increasing the activity 
of β-lactamase degrading antibiotics [11]. Penicillin and 
cephalosporin are two compounds of β-lactam group with the main 
structure of N-heterocyclic carbonyl in which it activates PBPs in the 
formation of bacterial cell walls. Given that, the analogues of 
curcumin with the main structure resembling β-lactam is suspected 
to have antibacterial potential. Twelve PBPs have been 
characterized in E. coli [1]. These proteins are divided into two 
groups that are high and low molecular weight (MW). High 
molecular weight PBP1a, PBP1b, PBP2 and PBP3 are bifunctional 
enzymes with DD-transpeptidase and transglycosidase activities. 
Seven PBPs with low BM are found in E. coli, but not essential. E. coli 
is missing gene in all PBPs with low molecular weight, but it still 
lives in the medium with PBP2 and PBP3, at least either PBP1a or 
PBP1b becomes very important since they have transpeptidase 
activities to synthesize the peptidoglycan [1]. Based on the test, the 
target protein is PBP-1a with code 5hl9. By using of such target 
protein, it is expected that the results of the docking can explain the 
potential of analogues of HGV-6 compounds D144, D154 and D156. 
The results of the research above have led us to carry out molecular 
docking test for the four compounds with the main structure S-
heterocyclic. To find out the ligand-protein interaction, the interaction 
part of the compounds is clearly described. It is the basis for studying the 
interaction of ligands with receptor proteins of bacterial cell walls. 




4-one (D154); 3,5-bis-(3´,5´-dichloro-4´-hydro xybenzylidene)-
tetrahydro-4H-thiopyran-4-one (D156); 2,6-bis-(3´,5´-dichloro-4´-
hydroxybenzylidene)-cylcohexanone (HGV-6), PBP 1a). 
Instrumentation 
The molecular docking was using a Personal computer with Intel 
core i3-6006U 2.0 GHz, ram 4GB, window 7 operating system. The 
Molecular docking procedure was performed using the Molecular 
Operating System (MOE) software version 2015.01.01. 
Procedure 
Ligand structure preparation 
The four compounds and ampicillin as reference molecules from 
molecular docking simulation were built with a two dimensional 
model and formed with MOE software. The conformation 
determination was using MOE software by import conformation, 
then the minimum energy was calculated. 
Protein validation (5HL9) 
The protein crystals had a crystal resolution of 2.7 Å with 78% of the 
protein chain having a high fit residue to electron density and no 
outlier. Native ligand alignment and dock ligand alignment were 
performed to ensure that the 5HL9 protein was suitable for use. 
Docking simulation 
3D Penicillin Binding Protein (PBP-1a) was obtained from Protein 
Data Bank (https://www. rcsb. org/structure/5hl9; code ID, PDB: 
5hl9) [12]. The protein contains reference molecule which was 
ampicillin as native ligand. The protein binding site was regulated 
using an atom ligand selection module in MOE and ampicillin 
binding site was used in the crystal structure as a reference. The 
binding site sequence was set using the MOE program. Hydrogen 
was added to complete the protein structure using the Protonate 3D 
program on MOE, only the ligand and protein chain were selected 
from the crystal structure. The protein was then aligned using the 
Align MOE module. In the docking simulation process, placement 
was set on the triangular matcher, rescoring was set with the 
London dG parameter and the conformation number was set at 10 
poses. The selected conformation with rmsd value<2Å was used for 
molecular docking [13]. The results of the docking of output file in 
the form of mdb with some conformation were compared to the 
results of docking of native ligand and positive control of ampicillin. 
All docking conformations were analyzed and the best value in the 
right pose was chosen for further interaction studies [14]. 
RESULTS AND DISCUSSION 
The research on D144, D154 and D156 was evaluated in silico as 
antibacterial. Molecular docking of the four compounds to β-lactam 
receptor was performed according to the basic components of the 
formation of D-Alanil-D-Alanine at the peptidoglycan formation 
stage. Transport enzyme D-Alanil-D-Alanine was D-Alanil-D-Alanine 
decarboxylase (DACA). Protein with code ID, PDB: 5HL9 was 
provided by the protein data bank. The protein containing reference 
molecule was ampicillin as the native ligand [15]. Validation of 
molecular docking protocols was conducted to ensure that the 
receptors were suitable for use in the molecular docking process. 
Based on the protein validation process, it obtained a root mean 
square deviation (RMSD) of 1.5042 Å where its value was less than 
2Å indicating that the docking method with 5HL9 receptor was valid 
and suitable for the further docking process [9] fig. 2. 
 
 
Fig. 2: Alignment native ligand (cyan) and docked ligand 
(yellow) PDB ID: 5HL9 
 
The best suit of maximum number of interactions had been analyzed, 
indicated by the S value in the MOE software. The best docking pose of 
10 conformations of each compound analyzed for interaction research. 
Docking results indicating the lowest binding energy cluster were 
considered as representative binding states. The minimum binding 
energies showed that target proteins were docked successfully with 
ligand molecules as an antibacterial agent [16]. Docking result 
revealed the strongest interaction had the right pose. Protein ligand 
interactions were visualized in 2D and 3D using MOE table 1. 
 
Tabel 1: Docking results with protein PDB ID 5HL9 
Compound S E_conf E_place E_score1 E_refine No. of Conf 
D144 -9.794 16.071 -58.138 -9.488 -26.494 10 
D154 -10.196 21.145 -55.990 -10.049 -20.787 10 
D156 -12.260 20.316 -62.222 -11.129 -23.352 10 
HGV-6 -11.795 43.583 -82.049 -12.013 -28.683 10 
Ampicilin -13.649 -47.261 -57.702 -9.794 -46.015 10 
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The results of D144, D154 and D156 docking using IDB ID receptor: 
5HL9 with HGV-6 and ampicillin as a reference show the docking 
scores of-9,7942,-10,1961,-12,2604. From the three ligands, it was 
seen that D156 had the lowest docking score, meaning that D156 
had the best antibacterial potential to interact with the target 
protein. In general, the difference in the electronegative group 
substituents in a compound affected the potential of the compound. 
Native ligand of ampicillin showed important amino acids that 
interacted with target proteins such as Asn574, Thr701, Ser510, Lys698. 
In its interactions, ampicillin involved O (C = O) atom from the carbonyl 
amide group interacting with Asn574 residues via hydrogen bonds (H-
acceptor), carbonyl O (C = O) in carboxylic group interacting with 
Thr701 via hydrogen bonds (H-acceptor) and the carboxylate group of O 
(OH) with Ser510 and Lys698 interacting via ionic bonds fig. 3. 
 
  
Fig. 3: Binding surface and ligand interaction of ampicillin with 5HL9 
 
D144 interacted with amino acid Asn574, involving the interaction 
of phi coordination bonds in the benzene ligand group with H atoms 
on Asn574. This interaction had similarities with native ligand 
namely involving Asn574, so the compound had potential as an 
antibacterial fig. 4. 
Compound D154 with two Cl substitute had no antibacterial activity 
against the target protein, even though the docking score showed 
greater than compound D144 who having one Cl substituent fig. 5. 
That was because the geometry of Cl atom formed tetrahedral sp3 in 
ortho position would disturb the other atoms around it (steric 
factors) so that it could inhibit resonance into the aromatic ring. The 
steric effect of the Cl atom in ortho position caused the compound 
ability to resonate towards the Cl substituent in para position, so the 
compound’s electrophilicity decreased so there was no interaction 
with the target protein. D156 showed similar interaction with native 
ligand since the structure of test compound had an interaction 
involving the amino acid Ser510 via H donor and Asn574, H acceptor 
via hydrogen and semipolar bonds. Theoretically, chlorine atom 
would deactivate the benzene ring, but in silico illustrated that 
electronegative atom was the center of action other than carbonyl 
since it seemed that some amino acids could interact with it fig. 6. 
 
  
Fig. 4: Binding surface and ligand interaction of D144 with 5HL9 
 
 
Fig. 5: Binding surface and ligand interaction of D154 with 5HL9 
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Fig. 6: Binding surface and ligand interaction of D156 with 5HL9 
 
D156 had the greatest potential as an antibacterial than the other 
three D and HGV-6 compounds since it had the lowest s value and 
the most interacting with active residue. This means that D156 is 
most active as antibacterial than other D compound and HGV-6. This 
compound had two different substituent groups which were Cl and 
OH, where these groups are pharmacophores acting as binding sites 
of the target protein. A lower docking score with the right pose 
resulted in a better stability level of ligand and receptor [17]. The 
lower binding energy indicated, the more likely it was to accept this 
test compound as a drug [16]. 
HGV-6 showed interactions in the Cl atom interacting with Ser507 
via H-donor fig. 7. From the docking score, it was more potent than 
D144 and D154 but since the involved amino acid was not the same 
as native ligand, the compound had lower antibacterial properties 
than D156 fig. 7. 
 
  
Fig. 7: Binding surface and ligand interaction of HGV-6 with 5HL9 
 
CONCLUSION 
The research on the interaction of chemical ligands with proteins 
could be explained using the MOE docking program. Each compound 
had a different active site depends on the substituents, heteroatom 
groups, and molecular geometries. Hydrogen bonds were formed 
through the electrostatic interactions of electron pairs from the O 
carbonyl atom to amino group, semipolar bonds were formed due to 
the contribution of a free electron pair to another atom. D156 was 
stronger than other D and HGV-6 compounds through hydrogen and 
semipolar bonds to a protein target. 
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